Market revenue in 2022 | USD 250.8 million |
Market revenue in 2030 | USD 364.5 million |
Growth rate | 4.8% (CAGR from 2022 to 2030) |
Largest segment | Allergic aspergillosis |
Fastest growing segment | Chronic Aspergillosis |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allergic Aspergillosis, Chronic Aspergillosis, Invasive Aspergillosis |
Key market players worldwide | Pfizer Inc, Merck & Co Inc, Novartis AG ADR, Astellas Pharma Inc, Bayer AG, Mayne Pharma Group Ltd, Pulmatrix Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to aspergillosis treatment market will help companies and investors design strategic landscapes.
Allergic aspergillosis was the largest segment with a revenue share of 49.08% in 2022. Horizon Databook has segmented the Latin America aspergillosis treatment market based on allergic aspergillosis, chronic aspergillosis, invasive aspergillosis covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America aspergillosis treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America aspergillosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account